Entering text into the input field will update the search result below

Dyne Therapeutics submits IND application to initiate DYNE-251 trial for DMD

Dec. 02, 2021 8:39 AM ETDyne Therapeutics, Inc. (DYN)By: SA News Team

Duchenne muscular dystrophy genetic test

Hailshadow/iStock via Getty Images

  • Dyne Therapeutics (NASDAQ:DYN) announces the submission of an Investigational New Drug (IND) application to the FDA to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.